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Background: Non-adherence to HIV-treatment can have a negative impact on patients’ treatment success rates,
quality of life, infectiousness, and life expectancy. Few adherence interventions have shown positive effects on
adherence and/or virologic outcomes. The theory- and evidence-based Adherence Improving self-Management
Strategy (AIMS) is an intervention that has been demonstrated to improve adherence and viral suppression rates in
a randomised controlled trial. However, evidence of its cost-effectiveness is lacking. Following a recent review
suggesting that cost-effectiveness evaluations of adherence interventions for chronic diseases are rare, and that the
methodology of such evaluations is poorly described in the literature, this manuscript presents the study protocol
for a multi-centre trial evaluating the effectiveness and cost-effectiveness of AIMS among a heterogeneous sample
of patients.
Methods/design: The study uses a multi-centre randomised controlled trial design to compare the AIMS
intervention to usual care from a societal perspective. Embedded in this RCT is a trial-based and model-based
economic evaluation. A planned number of 230 HIV-infected patients are randomised to receive either AIMS or
usual care. The relevant outcomes include changes in adherence, plasma viral load, quality of life, and societal costs.
The time horizon for the trial-based economic evaluation is 12–15 months. Costs and effects are extrapolated to a
lifetime horizon for the model-based economic evaluation.
Discussion: The present multicentre RCT is designed to provide sound methodological evidence regarding the
effectiveness and cost-effectiveness of a nurse-based counselling intervention (AIMS) to support treatment
adherence among a large and heterogeneous sample of HIV-infected patients in the Netherlands. The objective of
the current paper is to describe the trial protocol in sufficient detail to allow full evaluation of the quality of the
study design. It is anticipated that, if proven cost-effective, AIMS can contribute to improved evidence-based
counselling guidelines for HIV-nurses and other health care professionals.
Trial registration: The study has been registered on clinicaltrials.gov (Identifier: NCT01429142).
Keywords: Adherence, AIMS, Economic evaluation, HIV, Intervention, Randomised controlled trial* Correspondence: e.j.m.oberje@uva.nl
1Department of Communication, University of Amsterdam, Amsterdam
School of Communication Research ASCoR, Kloveniersburgwal 48, 1012 CX,
Amsterdam, Netherlands
Full list of author information is available at the end of the article
© 2013 Oberjé et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Oberjé et al. BMC Health Services Research 2013, 13:274 Page 2 of 11
http://www.biomedcentral.com/1472-6963/13/274Background
In patients infected with HIV, viral replication can be
effectively suppressed with antiretroviral therapy (ART),
allowing the body’s immune system to restore and function
adequately [1]. Other primary outcomes of HIV treatment
are improved patient health, life expectancy, and quality
of life (QoL) [2]. Moreover, HIV transmission risks are
reduced substantially in patients with lower viral loads,
which is beneficial from a public health perspective
[3-5]. Although full viral suppression can be achieved by
(some) patients with lower adherence levels (70-90%)
[6-8], it is generally recommended that patients take at
least 90-95% of their medication for long-term suppres-
sion of viral replication, to minimise the risk of developing
viral resistance [9-11]. Meta-analyses have shown that the
quality of adherence support delivered by health care pro-
fessionals during usual care is key to achieving adequate
adherence levels and viral suppression [12,13]. Hence, in
addition to the advances in the available ARVs, high-quality
adherence support is a cornerstone of the major advances
made in improving the lives of people living with HIV, and
slowing down the spread of (resistant) HIV.
Non-adherence is associated with lower quality of life,
morbidity, mortality, avoidable productivity losses, and
health care costs [14-17]. In spite of the fact that many
HIV-clinics may currently offer high-quality ‘usual ad-
herence care’, achieving and/or sustaining high levels of
adherence remains a challenge to a substantial number
of patients [12]. Hence, specially developed adherence
interventions can still make a relevant contribution,
even in settings that already offer high-quality usual
adherence care [18].
Numerous HIV-treatment adherence interventions
have been developed and evaluated [12,13,19-24]. For
interventions to be assessed as effective, they have to
be superior to the usual care already provided in the clinic
where the intervention is studied [12,13]. Intervention
programmes also need to be well-accepted by patients and
clinicians, and tailored to the capacity of the clinics deliver-
ing HIV-care in order to be sustainable [25]. Ideally,
interventions should also provide proof of cost-effectiveness
among a representative sample of patients and clinics before
they are implemented in routine practices [26,27].
A recent systematic review of cost-effectiveness evalu-
ations of adherence interventions among patients with
other chronic conditions included thirteen randomised
controlled trials (unpublished data). Only one trial evalu-
ated cost-effectiveness of an adherence intervention among
patients treated for HIV [28]. The objective of this review
was to critically assess the trials with the Cochrane risk
of bias tool and the Drummond checklist for the quality
of economic evaluations, and examine cost-effectiveness
outcomes [29,30]. Risk of bias varied considerably between
trials. Moreover, a key issue was the lack of (accurate)reporting of the relevant research methodology: for ex-
ample, in 24% of the cases the Cochrane bias score
could not be directly coded (‘Unknown’). Regarding
the quality of cost-effectiveness evaluations, an average
of 44% of required elements for a sound economic
evaluation were reported. However, it was often not
clear from the articles whether elements were merely
not reported or not performed. The authors therefore
concluded that, amongst others, cost-effectiveness
evaluations of future adherence trials should be more
comprehensive, and that trial reports should improve
to allow more detailed evaluations of their methodology.
Publishing the full study protocols that specify the objec-
tives, study design, primary outcome measures, and analysis
strategy is therefore key. The objective of the current paper
is to describe a trial protocol of a cost-effectiveness evalu-
ation of an HIV-adherence intervention that reports the
information required to fully evaluate the study design.
The adherence improving self-management strategy (AIMS)
One of the few adherence interventions that showed
positive effects on both adherence and clinical outcomes
(in this case, undetectable HIV loads) is the Adherence
Improving self-Management Strategy (AIMS) [18,31]. This
intervention has been designed by behavioural scientists
and clinical staff, and was then adapted based on patient
feedback [18,31]. Central to AIMS is electronic adherence
monitoring with MEMS-caps (Aardex Ltd.). MEMS-caps
are electronic pill caps that register date and time of pill
bottle opening. The data obtained via the MEMS-caps can
be printed in simple but comprehensive plots that show
medication intake patterns over long time-periods, allowing
for a detailed analysis of adherence barriers and potential
solutions to deal with these for each individual patient.
Discussion of MEMS-data has been combined with HIV-
nurses’ usual adherence support practices, and enhanced
with motivational and self-management techniques [31].
During a pilot-study and randomised controlled trial, both
health care professionals and patients evaluated AIMS
positively. Moreover, AIMS has been shown to enhance
adherence and viral suppression rates among 133 patients
in a 9-months randomised controlled trial [18]. Upon
request of the health care professionals, who wanted to
first master the counselling intervention before applying it
in - for them - more challenging populations or circum-
stances, the trial was set up in two stages. In the first stage,
only Caucasian patients were included, and patients with
untreated drug addictions or untreated severe mental
illness were not approached. In the second stage, these
restrictions would be removed. Unfortunately, slower than
anticipated inclusion rates, changes in the nursing team,
and lack of budget prevented progression to stage two.
In addition, the trial did not include a cost-effectiveness
evaluation. For these reasons we decided to seek additional
Oberjé et al. BMC Health Services Research 2013, 13:274 Page 3 of 11
http://www.biomedcentral.com/1472-6963/13/274funding to conduct an economic evaluation of the AIMS
intervention among a heterogeneous sample of patients.
The present manuscript describes the study protocol and
the rationale behind the design choices.
Methods/design
The study was primarily designed by the core team of
the current project, consisting of three behavioural sci-
entists (authors MdB, JM, and HS), an infectiologist
(author JP), a nurse practitioner (author HEN), a health
economist (author SE), and three statisticians (authors WV,
LG, and ET). The team made decisions on the study design
and outcome measures regarding the effect- and economic
evaluations. After recruitment of seven HIV-clinics for
collaboration in the present multi-centre clinical trial,
infectiologists and HIV-nurses from these clinics were
visited twice to provide them with details regarding the
proposed study design. During these meetings, members
from the collaborating HIV-clinics were invited to provide
feedback on inclusion criteria and study procedures. This
input resulted in various improvements in the project de-
sign and was expected to result in more commitment to
the project from the participating clinics.
The study has been approved by the ethics commit-
tees of the Academic Medical Center Amsterdam, the
Netherlands, and of each participating centre, and reg-
istered on clinicaltrials.gov (Identifier: NCT01429142)
prior to study start.
Research questions
The overarching research questions addressed by this
project are:
Effectiveness evaluation
1. What are the effects of the AIMS-intervention in
comparison with usual care with respect to changes
in plasma viral load (primary outcome) and
adherence (secondary outcome)?
Economic evaluation
2. From a societal perspective, is the AIMS-intervention,
in comparison with usual care, preferable in
terms of costs, effects, and utilities?
(trial-based economic evaluation)
3. What is the incremental cost-effectiveness ratio
(ICER) of the AIMS-intervention in comparison
with usual care? (trial-based economic evaluation)
4. In comparison with usual care, is the AIMS-
intervention preferable in terms of costs and utilities
during the remaining life expectancy of the study
population? (model-based economic evaluation).
Design
The study uses a multi-centre RCT design. Participants are
randomised to either the AIMS-intervention or to usualcare. The trial flow and randomisation procedures are
shown graphically in Figure 1 (for treatment-experienced
patients) and in Figure 2 (for treatment-initiating patients).
Embedded in this RCT is a trial-based economic evaluation
and a modelling study to investigate the cost-effectiveness
and cost-utility of the AIMS-intervention versus usual care.
Participants selection and inclusion criteria
The study focus was initially on treatment-experienced
patients (as was the case in the previous studies), but
after visiting the participating clinics for their input on
the study protocol, the decision was made to also in-
clude treatment-initiating patients. The major arguments
for facilitating this change was that [a] it increases repre-
sentativeness of the study sample, and [b] substantial
gains can be made in treatment-effectiveness in the first
year of the treatment by enhancing involvement in care
and adherence to treatment (i.e., about 75% of the patients
who started medication achieve the treatment objective of
a plasma viral load concentration of 50 copies/ml or less
within 9 months; Monitoring Report 2012 p68, http://www.
hiv-monitoring.nl/index.php/nederlands/.
Given that the majority of the treatment-experienced
patients adhere very well to the treatment and have a
suppressed viral load [18], two selection criteria were
developed to select those patients who are more likely
to benefit from the intervention. A first selection was
that only those patients who had a detectable viral load
in the past 3 years (with the count starting after the
first 9 months of treatment to allow them to achieve an
undetectable viral load) are asked to participate in a
baseline adherence monitoring stage. After a minimum
of 2 months baseline adherence monitoring period
(long enough for any measurement effect on adherence
to dissipate) [18,32], only the patients with suboptimal
adherence during baseline are randomised. The data used
to determine these cut-off points come from the Stichting
HIV Monitoring (detectable viral load in the previous
3 years) and the prior RCT (suboptimal adherence) [18].
Stichting HIV Monitoring collects anonymous routine
clinical data from all HIV patients in clinical care in the
Netherlands. Using this database, the probability of a
viral load measurement of 50 copies or more during one
year of follow-up was estimated as a function of the time
since patients’ last detectable viral load prior to the one
year follow-up period (N = 4440). The analyses showed that
the more recent patients had a detectable viral load ≥50
copies/ml prior to the 12-month follow-up, the larger
the probability that they would have a detectable viral
load during the 12 month follow-up (unpublished data).
Based on these analyses, we decided that a meaningful
cut-off was to include patients who had a detectable
viral load ≥50 copies/ml in the past 3 years. Regarding
adherence, secondary analysis of the baseline data from
T=-1 Recruitment
8 weeks baseline period
8 weeks MEMS
T=0 Randomisation
Month 0
Intervention group Control group 1 Control group 2
N=50% N=25% N=25%
Intervention + 4 months MEMS Usual care + ≥2 months MEMS Usual care
T=1 Intervention + ≥2 months MEMS Usual care Usual care
Month 4-5
T=2 Intervention + ≥2 months MEMS Usual care + ≥2 months MEMS Usual care
Month 8-10
T=3 End of follow-up End of follow-up End of follow-up
Month 12-14
Figure 1 Trial flow for treatment-experienced patients.
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ful cut-off. These analyses revealed that for a BID regi-
men a cut-off of 95% adherence predicted the next viral
load (detectable-undetectable) best, and for a QD regi-
men this was 99%. The difference between QD and BID
can be explained based on the duration of drug action
versus the probability of patients skipping one or mul-
tiple doses sequentially [33]. Hence, treatment experi-
enced patients with a detectable viral load during the
last 3 years (after the first 9 months of treatment) were
selected initially, and from those patients with suboptimal
adherence (≤ 95% for BID or < 100% for QD) during the
baseline assessment are included and randomised.
Besides the inclusion criteria as described above for
treatment-experienced patients, treatment-initiating
patients were eligible for participation without any inclu-
sion criteria. The exclusion criteria for both treatment-
experienced and treatment-initiating patients are: (1)
age <18 years, (2) severe psychiatric disorders precluding
compliance with study procedures, (3) pregnancy, (4)
plan to interrupt treatment or change clinics in the
next fourteen months, (5) life expectancy less than one year
as determined by physician, (6) not able to communicatewith health care professionals without an interpreter, (7)
not taking medication autonomously.
Recruitment
Participants are recruited from seven HIV-clinics in the
Netherlands: The Academic Medical Center Amsterdam,
the Leiden University Medical Center Leiden, the Erasmus
Medical Center Rotterdam, the Slotervaart hospital
Amsterdam, the St. Lucas-Andreas hospital Amsterdam,
the Isala clinics Zwolle, and the HAGA hospital The
Hague. The first three are academic hospitals and the
other are non-academic hospitals. In total these centres
have approximately 5500 patients in care and each year
about 350–400 patients initiate treatment.
Estimates of recruitment rates were based on Stichting
HIV Monitoring data and the prior RCT [18]. About 50-60
% (i.e., 3000) of the 5500 treatment-experienced patients in
the eligible clinic were estimated to either have a detectable
viral load in the last 3 years or to have a detectable viral
load during the study inclusion period. Assuming a
50% refusal rate and 50% of the patients to have excellent
adherence [18], this leaves a sample of 1500/2 = 750
potential treatment-experienced study participants for
T=0 Recruitment and randomisation
Month 0
Intervention group Control group 1 Control group 2
50% 25% 25%
Intervention + 2 weeks readiness? Usual care + 1 month MEMS Usual care
or
Intervention + 1 month MEMS
T=1 Intervention + 3 months MEMS Usual care + 3 months MEMS Usual care
Month 1
T=2 Intervention + ≥1 months MEMS Usual care Usual care
Month 3-4
T=3 Intervention + ≥1 months MEMS Usual care Usual care
Month 6-7
T=4 Intervention + ≥2 months MEMS Usual care + ≥2 months MEMS Usual care
Month 9-10
T=5 End of follow-up End of follow-up End of follow-up
Month 12-14
Figure 2 Trial flow for treatment-initiating patients.
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16 months, based on the recruitment rates in the prior
RCT. Due to various external influences during the start-up
of the project (e.g., a large clinic had a personnel shortage
and started a year later), the inclusion period was extended
to 22 months.
The HIV-nurses in the clinics manage recruitment.
During routine clinical visits, they approach eligible pa-
tients and inform them verbally about the content and
objectives of the project. These objectives were formu-
lated in terms of ‘improving the quality of care’ rather
than ‘improving adherence’, in an attempt to cover up
the specific study hypotheses. Patients are also given the
information in writing and the standard 2-week period
for deciding on study participation according to the Dutch
ethical guidelines. Patients are at liberty to decide to start
immediately, knowing they can withdraw at any time
without any consequences for their treatment.
Sample size
During the initial grant application, a sample size was
computed based on the assumption that only non-adherent,treatment experienced patients would be approached.
However, following the input from participating clinics,
the final inclusion and exclusion criteria were formu-
lated as explained above. An updated sample size com-
putation was done after inclusion had been initiated,
which was submitted to (date: 27th February, 2013) and
accepted by (date: 15th April, 2013) the funder (ZonMw,
the Netherlands Organisation for Health Research and
Development) using actual trial data in order to enhance
accuracy of the estimates (the expected treatment effect is
the same in both computations, the other estimates were
adjusted to match then new criteria and available data).
The trial summary on clinicaltrials.gov includes both the
initial and later the updated computations.
The updated sample size computation is the following:
A sample of 230 patients (22 nurses) is required to
obtain 80% power to detect a significant intervention
effect on viral load for at least one of three time points
(for treatment-experienced patients: T1, T2, and T3;
for treatment-initiating patients: T3, T4, and T5) with
alpha = .05 (two-sided) and using a Bonferroni correction.
Viral load at baseline is used as a covariate. A multilevel
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treatment effects at the nurse level. The sample size
calculation is based on the following assumptions:
depending on the nurse, (a) 60% to 80% of treatment-
initiating patients have an undetectable viral load during
usual care (i.e. ≥ 6 months after start of ART), (b) 15% to
20% of treatment experienced-patients and all treatment-
initiating patients have a detectable viral load at baseline,
(c) this increases in the intervention condition compared
to the control condition by 5 to 20 percentage points,
(d) a nurse recruits on average 11 patients for the trial,
and (e) an expected maximum dropout of 10%.
Randomisation procedure
Discussions with clinicians revealed that it is not desir-
able to randomise clinics (out of fear for recruitment
bias) or nurses (logistically challenging, i.e. what to do
when an intervention patient comes in and their nurse is
ill, and only a control group nurse is present?). Hence,
the decision was made to individually randomise patients
within nurses, so that each nurse sees both intervention
and control participants.
Experienced patients with insufficient adherence dur-
ing the baseline measurement and treatment-initiating
patients are randomised 1:1 to either the intervention or
control condition. For each HIV-nurse, a random allo-
cation scheme, stratified for treatment-experienced and
treatment-initiating patients, is generated using computer-
generated blocks to balance treatment and control assign-
ments within nurses. The size of the blocks is random
(block sizes of four, six, and eight; the clinicians are not
made aware of this). Because of the combination of strati-
fication, randomly-ordered block sizes, and the control-
group blinding procedure described in the next paragraph,
it seems impossible for clinicians to predict consecutive
treatment assignments. In practice, the randomisation
is fully automated using the web-platform medAmigo™
(Aardex Group Ltd.).
Two additional procedures are integrated within the
randomisation process. First, the study is powered based
on the primary outcome measure of viral load. Data
from the prior RCT suggests that in order to evaluate the
effects on adherence a smaller sample size suffices. In order
to reduce the study burden for both patients and clinics, it
was therefore decided to monitor adherence among only
half of the control group (since MEMS-monitoring is
part of the intervention, all intervention participants
were monitored). Hence, control participants are assigned
randomly to using the MEMS-cap or not using the
MEMS-cap (control groups 1 and 2: see Figures 1 and 2).
Second, 33% of the treatment-experienced patients with
adequate adherence at baseline (>95% for BID and 100%
for QD) are being randomised to the control groups in
order to blind clinicians to the adherence status of controlparticipants (since non-adherence is an inclusion criterion).
Naturally, the treatment-experienced patients with adequate
adherence at baseline are not taken into account for effect-
iveness and economic evaluation.
Intervention and usual care
Although the overall intervention strategy is similar for
treatment-initiating patients and treatment-experienced
patients, the first intervention visit is different for both
groups. Below, presented first is the description of the
intervention as provided to treatment-experienced pa-
tients. Subsequently, the elements are described that are
unique for treatment-initiating patients.
The AIMS-intervention
The AIMS-intervention is a nurse-delivered, adherence-
supporting intervention, with MEMS-data printed in sim-
ple but detailed plots to assist the counselling strategy.
For the rationale behind the intervention, please see de
Bruin et al., 2005; 2010 [18,31].
The intervention protocol below describes the main
steps taken with those patients randomised to the inter-
vention group after their initial two months of MEMS-
baseline monitoring. The intervention is available on-line
through the web-platform medAmigo™ and can only be
accessed by downloading the MEMS monitors for patients
assigned to the intervention arm. The software used
for randomisation is also the software that guides the
HIV-nurses and patients through the intervention.
Each of the following intervention steps is shown on a
separate webpage:
1. The HIV nurse discusses practical, tailored information
regarding adherence and the consequences of (non)
adherence (verbally and using a simple graph).
2. The HIV nurse asks the patient to define a desired
level of adherence, based on seven exemplar
MEMS-reports varying from ‘regular and no missing
doses’ to ‘irregular and many missing doses’.
3. If a patient selects an insufficient level of adherence
(e.g., several missing doses; in practice this occurs
rarely), the HIV-nurse explores the reasons for this
with the aim to motivate the patient to strife for a
safe level of adherence.
4. After a patient selects the desired level of adherence,
the nurse enquires about the patients’ personal drives
and motives (e.g., ‘Why this level and not lower?’).
5. The patients’ own MEMS-data (i.e., actual adherence
level) is printed, and discrepancies between the desired
(step 4) and actual adherence is discussed, appealing to
the patients’ responses to Step 4 when a lack of
motivation seems to be an underlying issue.
6. The HIV-nurse and patient use the MEMS-report to
identify patterns of non-adherence (e.g., weekends or
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pattern; or the reasons for the most recent
occurrences of non-adherence if there is no obvious
pattern. The patient is encouraged to identify
solutions to deal with these problems, and the software
offers successful strategies from other patients.
7. The nurse and patient finish this session with
developing an action plan for the next period,
including an overall behavioural objective
(e.g., no missed doses) and detailed actions for how
to achieve this. If the behaviour requires the
development of a routine, if-then plans are
formulated [34]. The patient is offered a MEMS-view
cap, which has a display on top showing how often
the bottle has been opened that day. This serves as a
direct feedback mechanism for missed doses,
supporting the self-monitoring of adherence.
8. During subsequent intervention sessions, nurse and
patient evaluate whether the action plan was successful,
whether the patient has encountered difficult situations
and how they were dealt with, followed by printing and
discussing the new MEMS-report. If adherence
problems remain, potential causes and solutions are
discussed and formulated in action plans until the
patient reaches the desired adherence level.
9. When a patient has successfully improved
adherence, goals are set for the maintenance of
behaviour and to develop strategies for risk
situations that may disrupt the new routine.
The aim in this study is that patients reach their
desired level of adherence during the first 4–5 months
of the intervention, strive for behavioural maintenance
(i.e., make the achieved level a routine) during the next
4–5 months, followed by a follow-up period of another
4–5 months.
Adapted elements for treatment-initiating patients
randomised to the intervention
Generally, two trajectories can be distinguished with
respect to ART initiation. First, there are patients who
need to start ART quickly because they are in an advanced
stage of infection and have low CD4 cell counts. They
start with primary PCP prophylaxis and, if they tolerate
this well, ART is initiated approximately fourteen days
later. The second group of patients comprise those whose
HIV-infection has been diagnosed in an earlier stage of
the disease and who have been monitored for some time
in the clinic. Once patients approach the CD4 criteria to
start ART, these patients are informed that it is time to
initiate treatment and they are usually given (at least) a
few weeks to prepare themselves.
The adapted start-up phase of the intervention for
treatment initiating patients consists of the following:During the preparatory visit approximately two weeks
prior to ART initiation, the patient and nurse go through
steps 1–4 of the AIMS-protocol. Patients are advised that
finding a good routine immediately can be challenging,
and they are therefore provided with a choice to start with
a “readiness period”. This readiness period means that pa-
tients are given a MEMS-view cap with their prescribed
primary PCP prophylaxis (for patients with low CD4 count)
or fourteen multivitamins/vitamin C tables (for the other
intervention patients) for the next fourteen days, and try
to follow the medication intake schedule that they would
also use when starting with ART. Patients then return to
the clinic, MEMS-data is downloaded and discussed with
the HIV-nurse, and problems and successes are discussed.
The main objective of this readiness period is to offer pa-
tients the opportunity to develop some intake routines
prior to initiating ART, to identify and address key barriers,
and it allows the patient and health care provider to exam-
ine whether the patient is really ready to start. Patients
who do not want this practice period commence the
MEMS-monitoring directly with ART.
The control group: mapping usual care
Usual adherence care in the Netherlands is primarily deliv-
ered by HIV-nurses. In addition to supporting adherence,
HIV-nurses may discuss patients’ sexual behaviours as well
as their physical, social, and mental well-being. Hence,
adherence counselling is only one of the tasks, although
an important one, of HIV-nurse practice.
In published manuscripts of adherence interventions,
the usual care provided to control groups is typically
described using just two words: ‘usual care’ [12]. However,
the active content of usual care may vary considerably
between study sites, can influence adherence and con-
sequently clinical outcomes. Variability in the ‘quality’
of usual care has been shown to explain approximately
34% points of the difference in treatment success rates
among control groups only [12], and influences the
effect sizes obtained by the experimental interventions
[13]. Assessing usual care and controlling for variability in
usual care in the analyses is therefore an important element
of the current study.
In order to determine the content of usual adherence
care, all HIV-nurses are asked to fill out a semi-structured
questionnaire with nine open questions covering the
major categories of adherence support counselling
[12]. The questionnaire explores the adherence care
that nurses systematically deliver to all of their patients
(i.e., nurses’ usual care). The reported activities are then
coded using a taxonomy of behaviour change techniques,
previously used to reliably code intervention and usual care
content in meta-analyses of adherence interventions
(the taxonomy is available at http://www.marijndebruin.eu/
Meta/HIVadherence/Taxonomy) [12,13]. The questionnaire
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AIMS intervention) and after study completion.
Measures and flow of treatment-experienced patients
The design and measures are graphically displayed in
Figure 1 and in Table 1.
T = −1 (recruitment): The HIV-nurses approach eligible
patients and inform them verbally and in writing about the
content and objectives of the project and tasks per treat-
ment arm. If approached patients refuse to participate,
reason(s) are noted. Consenting patients commence with
a 2-month baseline MEMS-monitoring period.
T = 0 (randomisation): After the baseline monitoring
period, patients with adequate adherence (100% QD, >95%
BID) who are not assigned to control group 1 or 2 are
shown their MEMS-results, and then excluded from
further study procedures. Those with suboptimal adherence
are randomised to the intervention group, to control
group 1 (with MEMS-monitoring) or control group 2
(without MEMS-monitoring). Patients receive information
on the further study procedures and also complete
Questionnaire 1: QoL (SF-12v2), Health Care Consumption
(HCC), and demographic characteristics. Patients assigned
to the intervention group receive a MEMS-cap or a
MEMS-view cap (optional) plus the AIMS-intervention,
and continue using the MEMS-cap during the next
4–5 months. Patients assigned to control group 1 are
asked to use the MEMS-cap at least 2 months prior to the
following visit (without seeing the data). Patients assigned
to control group 2 hand in the MEMS-cap now and con-
tinue receiving usual care.
T = 1: 4–5 months after randomisation (depending on
their usual visit interval) patients return for the next
visit. The intervention group receives AIMS. All patients
fill out Questionnaire 2 (HCC+ SF-12v2). Patients assigned
to the intervention group are asked to continue using theTable 1 Overview of measurements per time point separate f
Treatment-experienced patients T = −1
Demographic characteristics
Plasma viral load
Health care consumption (HCC)
Quality of life (SF-12v2)
Adherence (MEMS-data)* x**
Treatment-initiating patients T = 0 T = 1
Demographic characteristics x
Plasma viral load x
Health care consumption (HCC) x
Quality of life (SF-12v2) x
Adherence (MEMS-data)* x** x
* MEMS-use varies per treatment arm. For specific details regarding MEMS-use, see
** Start of MEMS-measurement.MEMS-cap at least during the 2 months prior to the
following visit (T = 2).
T = 2: 8–10 months later (depending on their usual
visit interval) patients return for the next visit. The
intervention group receives AIMS. All patients fill out
Questionnaire 3 (HCC + SF-12v2). Patients assigned to
the intervention group and control group 1 continue
using the MEMS-cap at least during the 2 months prior
to the following visit (T = 3).
T = 3: The visit at month 12–15 after randomisation is
focused on completing trial participation. Patients in the
intervention group receive AIMS and are offered the
opportunity to continue using the MEMS-(view)cap and
AIMS. Patients in control group 1 may decide to continue
using the MEMS-(view)cap and are offered to receive AIMS
during the next non-study visit. All patients fill out Ques-
tionnaire 4 (SF-12v2, HCC, demographic characteristics).
Measures and flow of treatment-initiating patients
The design and measures are graphically displayed in
Figure 2 and in Table 1. There are a few differences
compared with the procedures described for the treatment-
experienced patients. Patients visit the clinic at inclu-
sion and randomisation (T = 0), at 2–4 weeks (T = 1),
3–4 months (T = 2), 6–7 months (T = 3), 9–10 months
(T = 4), and at 12–14 months (T = 5).
T = 0 (recruitment and randomisation): The HIV-nurses
approach eligible patients and inform them verbally and
in writing about the content and objectives of the project,
and the tasks depending on the arm of the assignment.
If approached patients refuse to participate, reason(s)
are noted. Consenting patients are randomised. Patients
complete Questionnaire 1 (SF-12v2, HCC, demographic
characteristics) at treatment initiation. Those randomised
to the intervention group receive the MEMS-view cap and
commence the AIMS start-up protocol, or start directlyor treatment-experienced and initiating patients
T = 0 T = 1 T = 2 T = 3
x x
x x x x
x x x x
x x x x
x x x x
T = 2 T = 3 T = 4 T = 5
x
x x x x
x x x x
x x x x
x x x x
‘measurements and patient flow’ section in text and Figures 1 and Figure 2.
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follow usual care procedures.
T = 1-T = 5: At T = 2, T = 3, and T = 4, they complete
Questionnaire 2, 3, and 4 (HCC+ SF-12v2). At T = 5, they
receive Questionnaire 5 (SF-12v2, HCC, demographic char-
acteristics). Patients assigned to the intervention group and
starting with ART continue using the MEMS-view cap and
receive AIMS support up to month 3–4 (T = 2). During the
next two periods (up to T = 3 and T = 4) patients assigned
to the intervention group continue using the MEMS-cap at
least during the last month prior to the following visit.
The last 3–4 months of the study (from T = 4 to T = 5)
is a follow-up period and intervention patients are re-
quired to use the MEMS-cap during at least 2 months
prior to the follow-up visit. Patients in control group 1
(controls with MEMS) are asked to use the MEMS-cap
during the first 3–4 months of ART (up to T = 2) and
during the last two months of the follow-up period
(before T = 5). Patients in control group 2 do not use
the MEMS-cap.
Analyses
Research question 1) effectiveness evaluation
The proportion of patients with an undetectable viral
load (<20, <25, or <40 copies/ml, depending on the clinic’s
viral load testing kit) is calculated along with corresponding
95% CIs for three time points (for treatment-experienced
patients: T1, T2, and T3; for treatment-initiating patients:
T3, T4, and T5) after the baseline for the intervention and
control groups, respectively, and plotted as a function
of time. Next, a repeated-measures multilevel analysis is
conducted with viral load status (undetectable/detectable)
at the 3 measurement points as the dependent variable and
group membership (intervention/control 1 and 2 together)
as the independent variable. The nesting of patients within
nurses is accounted for in the model by allowing the (log)
odds of an undetectable viral load to vary randomly among
nurses. Differences in treatment effectiveness among nurses
will be accounted for in the model by inclusion of a
corresponding random effect. Depending on the distri-
bution of the outcome, we select the most appropriate
model for analyses (i.e. regression analyses with log viral
loads, or logistic regression with detectable/undetectable).
For the full sample, the adherence level during the first
two months of the intervention and the last two months of
the follow-up period as measured with the MEMS-caps is
examined in two separate multilevel model including group
membership (intervention or control group 1) as the inde-
pendent variable, and including treatment stage (treatment-
experienced or treatment-initiating) as a covariate in the
model. We intend to explore whether repeated measures
analyses are possible, although this is complicated by the ab-
sence of baseline adherence for treatment-initiating patients
(so only two repeated measures) and the multi-level design.Research question 2 and 3) trial-based economic evaluation
The objective of the economic evaluation study is to
examine whether the delivery of AIMS-intervention
compared to care as usual is preferable in terms of costs,
effects, and utilities from a societal perspective. The time
horizon is the same as the study duration after the AIMS-
intervention is initiated (12–15 months).
This economic evaluation involves a combination of a
cost-effectiveness analysis (CEA) and a cost-utility analysis
(CUA). In a CEA, effects are presented in behavioural
(adherence) and clinical (plasma viral load) outcomes.
In the CEA, the incremental cost-effectiveness ratio (ICER)
is expressed as the incremental costs per percentage of
patients with detectable viral load. A brief health care
utilisation questionnaire (HCC) is used aimed at identifying
all relevant direct and indirect cost aspects (e.g., intervention
costs, health care costs, patient costs, and costs outside the
health care sector). The valuation of healthcare and patient
costs is based on the updated Dutch manual for cost
analysis in healthcare research [35]. Costs of medication
are calculated using prices based on Daily Defined Dosage
(DDD) taken from the Dutch Pharmacotherapeutic
Compass. Productivity costs are calculated by means of
the friction cost method. Registrations from nurses are
used to calculate the time spend on the intervention
each consultation. The primary outcome measures for
the cost-utility analysis are QALYs, based on the SF-12v2
utility scores [36,37]. In the CUA, the ICER is expressed
as the incremental costs per QALY. To demonstrate the
robustness (checked by non-parametric bootstrapping)
of our base-case findings a multi-way sensitivity analysis
is performed (e.g., by varying cost-prices and volumes
between minimum and maximum). The bootstrapped
cost-effectiveness ratios are plotted in a cost-effectiveness
plane. The bootstrapped ICERs are also depicted in a cost-
effectiveness acceptability curve showing the probability
that the AIMS intervention is cost-effective using a range
of ceiling ratios.
Research question 4) model-based economic evaluation
The time horizon of the Cost-Utility Analysis (CUA) is
extrapolated towards the remaining life expectancy of
the study population. The CUA is of major importance
since the impact of AIMS on viral load, costs, and QoL
reaches beyond the 12-month study period of the RCT. A
Markov Monte Carlo decision analytic model is developed
to calculate lifetime incremental costs and incremental
QALYs of AIMS in comparison with usual care. The model
combines the results of the clinical study and data from the
medical literature. In the modelling study we also perform
probabilistic sensitivity analysis to test parameter uncertainty
and to construct cost-effectiveness acceptability curves. Fu-
ture costs and effects are discounted according to the Dutch
guidelines for cost calculations in health care [35].
Oberjé et al. BMC Health Services Research 2013, 13:274 Page 10 of 11
http://www.biomedcentral.com/1472-6963/13/274Discussion
The theory- and evidence-based Adherence Improving
self-Management Strategy (AIMS) is a nurse-based inter-
vention that has been demonstrated to improve adherence
and viral suppression rates in a randomised controlled trial.
However, evidence on its cost-effectiveness is lacking. Fol-
lowing a recent review suggesting that cost-effectiveness
evaluations of adherence interventions for chronic diseases
are rare and that their methodology is poorly described in
the literature, this manuscript presents the study protocol
for the economic evaluation of AIMS.
The present multi-centre RCT is designed to provide
sound methodological evidence regarding the effectiveness
and cost-effectiveness of AIMS to support treatment
adherence among a large and heterogeneous sample of
HIV-infected patients in the Netherlands. The objective
of the current paper is to describe the trial protocol of
the cost-effectiveness evaluation of the AIMS-intervention
that reports the information required to fully evaluate
the study design on methodological quality. Compre-
hensiveness of evidence should be optimal to guide
implementation decisions efficiently. The AIMS-study is
therefore designed to be consistent with the Drummond
checklist, Cochrane guidelines, and CONSORT guide-
lines for trial reporting [29,30,38].
A large part of behaviour change counselling in daily
practice is offered by nurses. Despite that they can offer
high-quality adherence support, there is rarely high-quality
evidence available in support of this important work.
We hope that the AIMS-study can contribute to this
evidence-base by demonstrating the efficiency of adherence
counselling by well-trained nurses. We realise, however,
that the practical value will eventually depend on the
success of wide-scale implementation and continuation
of AIMS. We therefore expect, in case of proven cost-
effectiveness, to develop a dissemination project with
the relevant stakeholders and to use the results of this
study for advancing usual care guidelines.
Trial status
Active, recruitment recently finalised.
Consent
Written informed consent was obtained from the patients
for the publication of this report and any accompanying
images.
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